New shot Mim8 shows promise for hemophilia a in safety switch study

NCT ID NCT05878938

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 helps prevent bleeding episodes by doing the job of a missing clotting factor. The study included 61 adults and teens who received Mim8 injections under the skin once a week, every two weeks, or once a month for about 6 to 12 months. The main goal was to track any side effects that occurred during the switch.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AKH - Klin. Abt. f. Haematologie u. Haemostaseologie

Vienna, 1090, Austria
AOU Careggi Firenze

Florence, Tuscany, 50134, Italy
Arthur Bloom Haemophilia Centre

Cardiff, CF14 4XW, United Kingdom
Augusta Univ/Childrens Hosp-GA

Augusta, Georgia, 30912, United States
Azienda Ospedaliera Santobono Pausilipon - U.S.D. Centro Regionale Pediatrico Malattie della Coagulazione

Naples, 80122, Italy
Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon

Naples, 80122, Italy
Belfast City Hospital

Belfast, BT9 78B, United Kingdom
Birmingham Children's Hospital

Birmingham, United Kingdom
Central Michigan University

Detroit, Michigan, 48201, United States
Charlotte Maxeke Johannesburg Academic Hospital

Parktown, Johannesburg, Gauteng, 2193, South Africa
Children's Hospital Los Angeles - Endocrinology

Los Angeles, California, 90027, United States
Cliniques universitaires Saint-Luc - Service Hématologie

Brussels, 1200, Belgium
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy
Hospices Civils de Lyon- Hopital Louis Pradel-1

Bron, 69500, France
Hospital Regional Universitario de Málaga

Málaga, 29010, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Kyung Hee University Hospital at Gangdong

Seoul, 05278, South Korea
McMaster University

Hamilton, Ontario, L8N 3Z5, Canada
Michigan State University

East Lansing, Michigan, 48824, United States
Nara Medical University Hospital_Pediatrics

Nara, 634-8522, Japan
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States
Penn State MS Hershey Med Ctr

Hershey, Pennsylvania, 17033-2360, United States
Royal Free Haemophilia Comprehensive Care Center

London, NW3 2QG, United Kingdom
Royal Free Haemophilia Comprehensive Care Centre

London, NW3 2QG, United Kingdom
Royal Hallamshire Hospital

Sheffield, S10 2JF, United Kingdom
Rush University Med. Cntr

Chicago, Illinois, 60612, United States
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
St Joseph's Hospital Foundation

Tampa, Florida, 33607, United States
UC Davis Medical Center

Sacramento, California, 95817, United States
UC Denver Hemoph & Thrombo Ctr

Aurora, Colorado, 80045, United States
Univ Hosp Cleveland Med Ctr

Cleveland, Ohio, 44106, United States
University of Iowa_Iowa City

Iowa City, Iowa, 52242, United States
Universitätsklinik für Innere Medizin V

Innsbruck, 6020, Austria
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie

Bonn, 53127, Germany
Vanderbilt U Med Ctr_Nashville

Nashville, Tennessee, 37212, United States
Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain

Berlin, 10249, Germany

Conditions

Explore the condition pages connected to this study.

HAEMOPHILIA A HAEMOPHILIA A WITH INHIBITORS